SCHEMBL7606207

SCHEMBL7606207

CC(C)(O)c1ccc2c(c1)c(OCc1ccccc1)c(N(C=O)c1cccnc1)n2Cc1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.39
HDAC6 Q9UBN7 3/20 0.39
ALOX5AP P20292 2/20 0.36
ALOX5 P09917 1/20 0.36
PKM P14618 1/20 0.36
GPBAR1 Q8TDU6 2/20 0.36
HDAC8 Q9BY41 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.34
LRRK2 Q5S007 1/20 0.34
SRPK3 Q9UPE1 1/20 0.34
TBXA2R P21731 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
TSHR P16473 2/20 0.34
USP2 O75604 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7607138 0.94 HDAC1 (0.37) HDAC1HDAC6ALOX5APALOX5PKM
SCHEMBL7555714 0.89 HDAC6 (0.45) HDAC1HDAC6ALOX5APALOX5HDAC8
SCHEMBL7608458 0.87 HDAC1 (0.40) HDAC1HDAC6PKMHDAC8CYP11B2
SCHEMBL7606176 0.86 HDAC6 (0.44) HDAC1HDAC6PKMHDAC8CYP11B2
SCHEMBL7551884 0.84 HDAC6 (0.44) HDAC1HDAC6ALOX5APALOX5HDAC8
SCHEMBL7607178 0.84 PKM (0.36) HDAC1HDAC6PKMGPBAR1HDAC8
SCHEMBL7613735 0.83 HDAC6 (0.44) HDAC1HDAC6ALOX5HDAC8PTGDR2
SCHEMBL7606062 0.82 HDAC6 (0.45) HDAC1HDAC6PKMHDAC8SMN1; SMN2
SCHEMBL7612615 0.80 MAPT (0.41) HDAC1HDAC6PKMALDH1A1CYP1A2
SCHEMBL7611332 0.80 HDAC6 (0.44) HDAC1HDAC6HDAC8SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6436965-B1 INHIBITION OF PHOSPHODIESTERASE; 3-CARBOCYCLIC(ALKYL)OXY-2-ARYL(ALKYL)AMINOCARBONYL-1-ARYL(ALKYL)INDOLE OR AZAINDOLE DERIVATIVES MERCK FROSST CANADA & CO. (CA) 2002-08-20 US claimed
US-20020068756-A1 PDE IV inhibiting amides, compositions and methods of treatment MERCK FROSST CANADA LTD. (CA) 2002-06-06 US claimed
US-6436965-B1 INHIBITION OF PHOSPHODIESTERASE; 3-CARBOCYCLIC(ALKYL)OXY-2-ARYL(ALKYL)AMINOCARBONYL-1-ARYL(ALKYL)INDOLE OR AZAINDOLE DERIVATIVES MERCK FROSST CANADA & CO. (CA) 2002-08-20 US disclosed
US-20020068756-A1 PDE IV inhibiting amides, compositions and methods of treatment MERCK FROSST CANADA LTD. (CA) 2002-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068756-A1 PDE IV inhibiting amides, compositions and methods of treatment PDE3A, PDE3B, PDE4A HDAC1 45/4885HDAC6 59/4885ALOX5AP 2416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.